ANVS News and Press, Annovis Bio Inc. From 11/27/23

2023-11-27 14:53:19 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Bio reports Q3 results Annovis Bio shares fall after pricing units offering at discount Seeking Alpha’s Quant Rating on Annovis Bio ...

BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that...

2023-11-21 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-08 17:36:49 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Bio shares fall after pricing units offering at discount Annovis Alzheimer's study gets green light from safety monitors Seeking Alpha ...

BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announ...

Buntanetap lowers the levels of TDP43, NfL, and GFAP Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making it possible to follow the changes in biomarkers during the cours...

2023-10-31 10:00:02 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further details see: Sarepta Therapeutics, Petmed Express among healthcare movers

2023-10-31 09:30:54 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Alzheimer's study gets green light from safety monitors Annovis Bio announces launch of proposed public offering Seeking Alpha’s Qua...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten public...

2023-10-30 18:18:26 ET More on Annovis Bio Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts Annovis Bio announces launch of proposed public offering Alzheimer's drug developers get lift from Anavex results Seeking Alpha’s Quant Rati...